Accelerate Diagnostics Inc (NASDAQ:AXDX) has received an average broker rating score of 1.50 (Buy) from the four brokers that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold recommendation and three have given a strong buy recommendation to the company.
Brokers have set a twelve-month consensus price target of $26.50 for the company and are predicting that the company will post ($0.31) earnings per share for the current quarter, according to Zacks. Zacks has also given Accelerate Diagnostics an industry rank of 184 out of 265 based on the ratings given to its competitors.
A number of equities research analysts recently weighed in on AXDX shares. BTIG Research cut shares of Accelerate Diagnostics from a “buy” rating to a “neutral” rating in a research note on Wednesday, December 13th. They noted that the move was a valuation call. Zacks Investment Research cut shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research note on Monday, January 15th. ValuEngine upgraded shares of Accelerate Diagnostics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, BidaskClub upgraded shares of Accelerate Diagnostics from a “hold” rating to a “buy” rating in a research note on Thursday, February 22nd.
Shares of Accelerate Diagnostics (NASDAQ AXDX) opened at $25.20 on Tuesday. The stock has a market capitalization of $1,444.35, a price-to-earnings ratio of -21.72 and a beta of 2.22. Accelerate Diagnostics has a one year low of $16.75 and a one year high of $30.45.
Accelerate Diagnostics (NASDAQ:AXDX) last posted its earnings results on Thursday, February 15th. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.05. The company had revenue of $2.10 million for the quarter. Accelerate Diagnostics had a negative return on equity of 54.66% and a negative net margin of 1,520.99%. sell-side analysts expect that Accelerate Diagnostics will post -1.2 EPS for the current fiscal year.
In related news, Director Jack W. Schuler acquired 10,000 shares of the business’s stock in a transaction that occurred on Thursday, February 22nd. The shares were acquired at an average cost of $25.21 per share, for a total transaction of $252,100.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jack W. Schuler acquired 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The shares were bought at an average price of $24.95 per share, for a total transaction of $499,000.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 45,100 shares of company stock worth $1,130,850. Company insiders own 50.00% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Cpwm LLC bought a new stake in shares of Accelerate Diagnostics during the fourth quarter valued at about $202,000. UBS Asset Management Americas Inc. acquired a new position in Accelerate Diagnostics during the fourth quarter worth about $233,000. Teacher Retirement System of Texas acquired a new position in Accelerate Diagnostics during the fourth quarter worth about $292,000. MetLife Investment Advisors LLC acquired a new position in Accelerate Diagnostics during the fourth quarter worth about $297,000. Finally, Voya Investment Management LLC grew its holdings in Accelerate Diagnostics by 13.9% during the second quarter. Voya Investment Management LLC now owns 12,193 shares of the medical research company’s stock worth $333,000 after acquiring an additional 1,486 shares during the period. Institutional investors and hedge funds own 44.86% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/04/07/zacks-accelerate-diagnostics-inc-axdx-receives-consensus-rating-of-buy-from-analysts.html.
About Accelerate Diagnostics
Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.
Get a free copy of the Zacks research report on Accelerate Diagnostics (AXDX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.